HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure.

Abstract
Although myelodysplastic syndromes are heterogeneous disorders comprising a benign subset of bone marrow failure similar to aplastic anemia, no laboratory test has been established to distinguish it from bone marrow failures that can evolve into acute myeloid leukemia. Plasma thrombopoietin levels were measured in 120 patients who had myelodysplastic syndrome with thrombocytopenia (< 100 × 10(9)/L) to determine any correlation to markers associated with immune pathophysiology and outcome. Thrombopoietin levels were consistently low for patients with refractory anemia with excess of blasts, while patients with other myelodysplatic syndrome subsets had more variable results. Patients with thrombopoietin levels of 320 pg/mL and over had increased glycosylphosphatidylinositol-anchored protein-deficient blood cells (49.1% vs. 0%), were more likely to have a low International Prognostic Scoring System (IPSS) score (≤1.0, 100% vs. 65.5%), a higher response rate to immunosuppressive therapy (84.2% vs. 14.3%), and a better 5-year progression-free survival rate (94.1% vs. 63.6% for refractory cytopenia with unilineage dysplasia; 100.0% vs. 44.4% for refractory cytopenia with multilineage dysplasia). In conclusion, increased plasma thrombopoietin levels were associated with a favorable prognosis of bone marrow failure and could, therefore, represent a reliable marker for a benign subset of myelodysplastic syndrome.
AuthorsYu Seiki, Yumi Sasaki, Kohei Hosokawa, Chizuru Saito, Naomi Sugimori, Hirohito Yamazaki, Akiyoshi Takami, Shinji Nakao
JournalHaematologica (Haematologica) Vol. 98 Issue 6 Pg. 901-7 (Jun 2013) ISSN: 1592-8721 [Electronic] Italy
PMID23403320 (Publication Type: Journal Article)
Chemical References
  • Biomarkers
  • GPI-Linked Proteins
  • Immunosuppressive Agents
  • Thrombopoietin
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers (blood)
  • Blood Cells (metabolism)
  • Bone Marrow (pathology)
  • Female
  • GPI-Linked Proteins (deficiency, metabolism)
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes (blood, diagnosis, drug therapy)
  • Prognosis
  • ROC Curve
  • Thrombocytopenia (blood)
  • Thrombopoietin (blood)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: